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Abstract
Aims Biomarkers are increasingly being used in the
management of patients with chronic heart failure (HF).
Galectin-3 is a recently developed biomarker associated
with ﬁbrosis and inﬂammation, and it may play a role in
cardiac remodeling in HF. We determined its prognostic
value in patients with chronic HF.
Methods and results Patients with chronic HF (New York
Heart Association functional class III or IV) who partici-
pated in the Deventer–Alkmaar heart failure study were
studied. Galectin-3 levels were determined at baseline
using a novel optimized enzyme-linked immunosorbent
assay. Univariate and multivariate analyses were used to
determine the prognostic value of this biomarker. We
studied 232 patients; their mean age was 71 ± 10 years,
72% were male, and 96% were in NYHA class III. During
a follow-up period of 6.5 years, 98 patients died. Galectin-
3 was a signiﬁcant predictor of mortality risk after
adjustment for age and sex, and severity of HF and renal
dysfunction, as assessed by NT-proBNP and estimated
glomerular ﬁltration rate, respectively (hazard ratio per
standard deviation 1.24, 95% CI 1.03–1.50, P = 0.026).
Conclusion Plasma galectin-3 is a novel prognostic
marker in patients with chronic HF. Its prognostic value is
independent of severity of HF, as assessed by NT-proBNP
levels, and it may potentially be used in the management of
such patients.
Keywords Galectin-3  Chronic heart failure 
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Introduction
Heart failure (HF) is a large medical and epidemiological
problem, and recent studies, both in acute and chronic HF,
indicate that it is still associated with a high morbidity and
mortality [1–3]. Early identiﬁcation of high-risk patients
may favorably affect outcome and biomarkers are
increasingly being recognized to have important clinical
value in this respect [3]. After the initial insult to the
myocardium, HF is a disease with autonomic progression
associated with ventricular dysfunction and cardiac
remodeling [4]. Natriuretic peptides, in particular brain
natriuretic peptide (BNP) and its N-terminal part NT-
proBNP, are increasingly being used to guide the man-
agement of HF patients [3]. Although this concept has
proven to be successful, BNP and NT-proBNP values are
very much inﬂuenced by many factors including age, renal
function, and anemia [5]. As a result, the search for new
biomarkers, which might reﬂect other disease processes,
and which might be of additional and independent value
has continued. Indeed, with the acknowledgement of
remodeling as a determinant of disease progression and
poor prognosis, it has become imperative to identify those
patients with the highest risk of adverse outcome, thus
enabling a more personalized management of HF.
Galectin-3 is a soluble b-galactoside-binding lectin [6]
that plays an important regulatory role in cardiac ﬁbrosis
and remodeling, which are key contributing mechanisms to
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found to be increased in patients with acutely decompen-
sated and unstable HF [7, 8]. The involvement of galectin-
3 in the development of ﬁbrosis has been demonstrated not
only in the liver [9] and in the kidney [10], but in the heart
as well [11, 12]. Taken together, these observations sug-
gest that measuring galectin-3 levels may potentially be
useful in a wider range of HF patients [13] to determine
their risk in general and to examine the value of this new
biomarker when added to conventional risk markers.
Accordingly, we studied the clinical value of galectin-3 in
a population of patients with stable advanced HF, who had
been very well clinically characterized, and who were
enrolled in the Deventer–Alkmaar heart failure study
(DEAL-HF) [14].
Methods
Study design and patient population
The original DEAL-HF study was a prospective, random-
ized, parallel group, controlled study conducted at two
regional teaching hospitals in The Netherlands. The study
design and methods have been described in detail previ-
ously [14]. Brieﬂy, 240 patients with the NYHA functional
class III or IV HF were randomized between 2000 and
2003 to a disease management program or not. The pri-
mary endpoints were all-cause mortality and hospitaliza-
tion for HF and the duration of the study was 12 months. In
the present study, the follow-up was extended, and only
vital status (and not intermittent hospitalizations) were
assessed during long-term follow-up, for obvious reasons
[15]. The ofﬁcial day of assessment was September 15,
2006. The protocol was approved by the local Medical
Ethics Committees and the study complied with the Dec-
laration of Helsinski. Written informed consent was given
by all patients.
Galectin-3 measurements
At baseline, 10 mL of blood was drawn from the antecu-
bital vein of all patients and transferred in chilled dispos-
able tubes containing aprotinin. The blood samples were
then centrifuged at 3,500 rpm for 15 min at 4C, the
plasma was transferred into 1 mL cryotubes, and stored at
-70C for later analyses.
Plasma galectin-3 levels were determined using a novel
and optimized enzyme-linked immunosorbent assay kit
(Galectin-3 Assay
TM, BG Medicine, Waltham, MA, USA)
and were measured on a Bio-tekELx800 microplate reader
(Biotek Instruments, Winooski, VT, USA). Calibration of
the assay was performed according to the manufacturer’s
recommendations and values were normalized to a stan-
dard curve.
Of the 240 patient baseline plasma samples, eight
samples had insufﬁcient sample volume remaining to per-
form the galectin-3 measurement. As such, there are a total
of 232 baseline galectin-3 measurement results.
Other biochemical measurements
NT-proBNP levels were determined by an immunoelec-
trochemiluminesence method (Elecsys, Roche Diagnostics,
Basel, Switzerland) [5].
The estimated glomerular ﬁltration rate (eGFR) as an
indicator of renal function, was estimated from serum
creatinine using a formula that accounts for the inﬂuence of
age on creatinine production, which has been validated in
patients with HF, and was described in detail elsewhere
(MDRD) [16].
Statistical analyses
Galectin-3 values were categorized into quartiles based
upon their distribution among all patients and a Kaplan–
Meier product limit analysis was performed. The log-rank
test was used to test equality of estimated survival distri-
bution functions across quartiles of galectin-3. In addition,
the association between galectin-3 level and the instanta-
neous relative risk of death from any cause was analyzed
using a Cox proportional hazards regression analysis and
Kaplan–Meier product limit estimation. A univariate Cox
proportional hazards regression model with galectin-3 as
the predictor variable was used to estimate the hazard ratio
(HR) and 95% conﬁdence interval (CI) associated with
baseline galectin-3 value and death from any cause.
Galectin-3 value was examined continuously [expressed
per standard deviation (SD)] and categorized as a binary
predictor variable based on a previously determined cut-off
value of 17.7 ng/mL, which represents the recommended
upper limit of normal value for galectin-3 (Personal com-
munication, BG Medicine Inc., Waltham, MA, USA,
February 2009). Evaluation of the assumption of propor-
tional hazards was positively evaluated by inspection of log
(-survival) values as a function of survival time across
galectin-3 categories. The Wald chi-square P value was
used to evaluate the statistical signiﬁcance of the Cox
regression model. Multivariable Cox regression models
were also evaluated to assess the effect of galectin-3 on
mortality after adjusting for NT-proBNP, age, gender, and
creatinine clearance rate. In one patient NT-proBNP mea-
surement was not available, therefore all multivariable
models including NT-proBNP were conducted based upon
231 patients. Results for baseline characteristics are pre-
sented as mean ± SD. Receiver operating characteristic
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123(ROC) curve analysis was performed. We considered
sensitivity and speciﬁcity of equal importance, in ROC
analyses, the best prognosticators for survival status were
considered to be those parameters that gave the highest
product of sensitivity and speciﬁcity for predicting death.
Spearman correlation coefﬁcients were calculated to
determine which clinical and biochemical variable had a
univariate correlation with Galectin-3. Statistical analyses
were performed using SAS software, version 9.1 (SAS
Institute, Cary, NC, USA).
Results
A total of 232 baseline plasma samples from HF patients,
enrolled in the DEAL-HF study, were available and
included in the analysis. Baseline characteristics grouped
according to the galectin-3 levels are depicted in Table 1.
Overall, mean age was 71 ± 10 years, 72% were male and
96% were in the NYHA functional class III. Co-morbidi-
ties included diabetes mellitus in 30% and chronic
obstructive pulmonary disease in 29%. The mean creati-
nine clearance rate was 55.0 ± 22.8 mL/min and the
median NT-proBNP level was 253 pmol/L (2,140 pg/mL).
The mean follow-up time of the surviving patients was
4.0 ± 1.9 years.
Galectin-3 values
One hundred and fourteen patients (49%) had galectin-3
plasma levels above the upper limit of normal cut-off value
of 17.7 ng/mL. For all study subjects, the mean levels of
galectin-3 across quartiles were 18.6 ± 7.8 ng/mL
(Table 1). Galectin-3 levels were associated with age
(r = 0.318, P\0.001), and younger patients had lower
levels. Galectin-3 was also associated with renal dysfunc-
tion (GFR) (r =- 0.619, P\0.001) and higher levels
were found in patients with more renal dysfunction.
Galectin-3 levels were also increased in patients with
higher NT-proBNP levels (r = 0.265, P\0.001). Finally,
a borderline, statistically signiﬁcant association was found
with body mass index (BMI) (r =- 0.154, P = 0.022).
There was neither a signiﬁcant correlation between galec-
tin-3 levels and left ventricular ejection fraction nor etiol-
ogy of HF.
Galectin-3 levels and mortality
Overall, 98 patients died during the follow-up period.
Patients who died were older (P = 0.03) and more often
male (P = 0.04). In addition, both NT-proBNP levels
(577 ± 751 vs. 363 ± 477 pmol/L, P = 0.01) and galec-
tin-3 levels (20.1 ± 8.1 vs. 17.5 ± 7.4 ng/mL, P = 0.01)
Table 1 Baseline demographic and clinical characteristics of the study population by quartile of galectin-3 levels
Baseline characteristic All subjects
n = 232
Galectin-3 quartile P value
1( \13.63
ng/mL)
n = 58
2 (13.63–17.63
ng/mL)
n = 59
3 (17.64–21.62
ng/mL)
n = 57
4( [21.62
ng/mL)
n = 58
Age, mean (SD) (years) 70.9 (10.0) 64.6 (11.7) 71.6 (8.9) 72.8 (8.9) 74.6 (7.0) \0.001
Male (%) 72.4 72.4 76.3 68.4 72.4 N/S
Ischemic etiology (%) 62.5 50.0 70.2 61.0 69.0 0.047
NYHA functional class (%)
III 96 97 100 93 93 N/S
IV 4 2 0 6 7 N/S
LVEF, mean (SD) 30.9 (9.4) 31.1 (10.0) 29.7 (8.2) 31.9 (8.7) 31.0 (10.6) N/S
BMI, mean (SD) (kg/m
2) 26.3 (4.7) 27.9 (5.3) 25.9 (4.1) 25.8 (4.7) 25.9 (4.3) 0.046
Diabetes mellitus (%) 30 28 22 35 33 N/S
COPD (%) 29 25 23 32 35 N/S
Smoker (%) 13 17 12 14 9 N/S
GFR, mean (SD) (mL/min) 55.0 (22.8) 72.7 (24.5) 56.0 (18.6) 49.2 (19.4) 42.3 (16.6) \0.001
NT-proBNP level, mean (SD)
(pmol/L)
456.0 (616.7) 291.1 (376.6) 353.8 (386.7) 526.5 (561.1) 651.2 (920.4) 0.005
Galectin-3 level, mean (SD) (ng/mL) 18.6 (7.8) 11.3 (1.6) 15.5 (1.3) 19.5 (1.2) 28.2 (9.0) –
Percentages may not sum to 100 due to rounding. P values are from one-way ANOVA comparison of means across quartiles of galectin-3
BMI Body mass index, COPD chronic obstructive pulmonary disease, LVEF left ventricular ejection fraction, NYHA New York Heart Asso-
ciation, SD standard deviation, N/S not signiﬁcant
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123were signiﬁcantly higher in patients who died, than in
survivors.
ROC curve analysis revealed an area under the curve
(AUC) of 0.612 [0.538–0.685], P = 0.004 for Galectin-3.
Similar results yielded for NT-proBNP: AUC of 0.611
[0.538–0.685], P = 0.004. We found that the highest
product of sensitivity and speciﬁcity was seen with gal-3
levels of 17.72 ng/mL.
Figure 1 shows the Kaplan–Meier survival curves
according to quartiles of galectin-3. There was a gradual
increase in all-cause mortality across the galectin-3 quar-
tiles (log-rank P = 0.048).
Adjustment for patient baseline age, gender, baseline
eGFR and baseline NT-proBNP value minimally attenu-
ated the association of baseline galectin-3 level with out-
come, with galectin-3 remaining a signiﬁcant predictor.
The effects of these covariates appear in Table 2. In the
fullest model that incorporates NT-proBNP, age, gender
and creatinine clearance rate, the HR associated with
galectin-3 per SD was HR 1.24 (95% CI 1.03–1.50,
P = 0.026).
The incremental risk of the combination of galectin-3,
dichotomized into below and above normal values with
NT-proBNP, dichotomized above and below the median,
was also considered. Figure 2 presents the mortality within
four categories of the combination of galectin-3 and
NT-proBNP. Patients with high baseline levels of both
galectin-3 and NT-proBNP were observed to have an
approximately 1.5- to 2-fold higher mortality rate com-
pared to patients in other categories (P = 0.036 for trend).
Discussion
The main ﬁnding of the present study is that galactin-3 is
an independent predictor of mortality in this population of
patients with moderate to advanced chronic HF. Although
increased levels of galectin-3 were associated with
increasing age, progressive renal dysfunction and severity
Fig. 1 Kaplan–Meier curves according to quartiles of baseline
galectin-3 values. Log-rank P = 0.048. Q1 galectin-3 values
\13.63 ng/mL, Q2 13.63–17.63 ng/mL, Q3 17.64–21.62 ng/mL, Q4
[21.62 ng/mL
Table 2 Univariate and adjusted multivariable hazard ratios for galectin-3 association with mortality
HR (95% CI) for galectin-3 P value
Univariate (galectin-3 only) per standard deviation (7.8 ng/mL) 1.24 (1.08–1.43) 0.003
?NT-proBNP 1.28 (1.07–1.52) 0.006
?NT-proBNP ? age ? gender 1.25 (1.05–1.49) 0.014
?NT-proBNP ? age ? gender ? GFR 1.24 (1.03–1.50) 0.026
The stated P value is associated with the regression coefﬁcient of galectin-3 in each model
0%
10%
20%
30%
40%
50%
60%
NT-proBNP > 253 pmol/L
galectin-3>
17.7ng/ml
galectin-3<
17.7ng/ml
Mortality
NT-proBNP < 253 pmol/L
 33.3%
(23/69)
 42.6%
(20/47)
 34.7%
(17/49)
 56.1%
(37/66)
Fig. 2 Mortality as a function of baseline galectin-3 and NT-proBNP
categories. The median value of NT-proBNP (253 pmol/L), was used
to deﬁne two levels of NT-proBNP concentration. Of the 232
subjects, 231 had both a galectin-3 and NT-proBNP measurement.
The number of patients in the each category is as follows: high
galectin-3 and high NT-proBNP (n = 66); low galectin-3 and low
NT-proBNP (n = 69); low galectin-3 and high NT-proBNP (n = 49);
high galectin-3 and low NT-proBNP (n = 47)
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123of HF as assessed by increasing levels of NT-pro BNP,
galectin-3 remained an independent prognostic marker.
The present data extend earlier ﬁndings in patients with
acutely decompensated HF [8] and in those with terminal,
end-stage HF who required mechanical circulatory support
[9]. In the study by van Kimmenade et al. [8], galactin-3
was measured in 599 patients with acute dyspnea who
presented to the emergency department, of whom 209 were
diagnosed as ‘‘acute HF’’. Galectin-3 levels were higher in
those with acute HF than in those who did not (9.2 vs.
6.9 ng/mL; P\0.001), and the ROC curve of galactin-3
for the diagnosis of HF was 0.72 (P\0.001) as compared
to a ROC curve for NT-pro BNP of 0.94 (P\0.001; dif-
ference with galectin-3 P\0.001). For predicting 60-day
mortality, ROC curves were higher for galectin-3 (0.74,
P\0.001) than for NT-pro BNP (0.67, P = 0.009; dif-
ference with galectin-3, P = 0.05). In the study by Milting
et al. [9], 55 patients with end-stage HF were compared to
40 healthy controls, and galectin-3 levels were higher in
HF patients than in controls (11 vs. 4.1 ng/mL, P\0.05),
but galectin-3 did not decrease after ventricular assist
device support (in contrast to BNP levels). However,
patients who died or in whom multi-organ failure devel-
oped, had signiﬁcantly higher galectin-3 levels compared
to those who successfully bridged to transplantation. In the
present study, galectin-3 levels were elevated in only half
of our population of patients with advanced but stable HF.
As a biomarker to detect (or exclude) HF, this percentage is
rather low, as compared to for example BNP in which
around 90% of similar patients were found to abnormal
levels [17]. In contrast to its diagnostic properties, the
prognostic value of galectin-3 appears to be high. Both in
the two earlier studies in acute unstable HF, as well as in
the present study in relatively stable HF patients, galectin-3
was an independent predictor of outcome during follow-up
and as such, it appears to be a promising new biomarker in
HF [18].
Galectin-3 promotes macrophage migration, ﬁbroblast
proliferation and collagen synthesis, or the development of
ﬁbrosis [14]. In a recent study, the independent association
between excessive extracellular matrix turnover and poor
outcome in patients with HF was reported and this was
particularly true for the serum collagen marker PIIINP
(N-terminal type III collagen peptide) [19]. Recent work
from Taiwan [20] has shown that Galectin-3 is signiﬁcantly
correlated with this PIIINP, but also with other (serum)
markers of extracellular matrix turnover, such as matrix
metalloproteinase-2 (MMP-2) and tissue inhibitor of
metalloproteinase-1 (TIMP-1).
Galectin-3 levels were signiﬁcantly associated with
the severity of renal dysfunction in this study, but
retained prognostic value after correction for eGFR. This
ﬁnding is interesting since increased galectin-3 is also
associated with renal ﬁbrosis [10], and the same process
may thus affect both heart and kidneys. Renal dysfunc-
tion is one of the most powerful predictors of prognosis
in HF and plays an important role in its pathophysiology
[21] and the ‘‘overlap’’ may thus also be mediated by
galectin-3.
After an initial insult to the myocardium, cardiac
remodeling occurs as a compensatory mechanism, and this
will ultimately lead to left ventricular dysfunction and HF.
This complex process with an increase of left ventricular
wall thickness and dilatation and reshaping of the left
ventricle leads to lengthening or hypertrophy of cardio-
myocytes with insufﬁcient angiogenesis leading to meta-
bolic and ischemic problems [22]. Activation and
proliferation of ﬁbroblasts, which increases the synthesis of
ﬁbrillar collagen and activates the inﬂammatory response,
plays an important role in this process [23–25]. Galectin-3
is likely to play a role in this process, and has been shown
to interact with various ligands located at the extracellular
matrix [26]. In a very recent study from the US, intraper-
icardial infusion of galectin-3 for 4 weeks in adult male
rats led to (1) enhanced macrophage and mast cell inﬁl-
tration, increased cardiac interstitial and perivascular
ﬁbrosis, and cardiac hypertrophy, (2) increased TGF-b
expression, and (3) decreased cardiac performance, as for
example shown by systolic and diastolic cardiac perfor-
mance [27]. Given these ﬁndings, it would be tempting to
speculate that blockade or inhibition of galectin-3 could
have favorably affect this process and be a target for
treatment, but to our knowledge, such data are not (yet)
available.
The main limitation of the current study is its relatively
small size. Furthermore, we measured galectin-3 on a
single time point and thus can only speculate on its
importance over time. Because of these limitations, we
regard our study mainly as a hypothesis-generating study.
Nevertheless, galectin-3 is a novel biomarker in patients
with HF, which seems to have important prognostic value.
Although it is generally elevated in HF, this prognostic
value is independent of the severity of disease, as assessed
by NT-proBNP levels.
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